Length of stay following percutaneous left atrial appendage occlusion: Data from the prospective, multicenter Amplatzer Amulet Occluder Observational Study.

To evaluate factors influencing the length of stay in patients undergoing percutaneous left atrial appendage occlusion (LAAO). Patient characteristics, procedural data and the occurrence of serious adverse events were analyzed from the AmplatzerTM AmuletTM Occluder Observational Study. Patients were divided into three groups: same day (S, 0day, n = 60, 5.6%) early (E, 1day, n = 526, 48.9%), regular (R, 2-3days, n = 338, 31.4%) and late (L, ≥4days, n = 152, 14.1%) discharge and followed up for 60 days. Procedure and device related SAE during the in-hospital stay (S: 0.0% vs. E: 1.0% vs. R: 2.1% vs. L: 23%, p<0.0001) were a major trigger for a prolonged in-hospital stay. Of the 37 subjects in the late discharge group with an SAE prior to discharge, cardiac or bleeding complications were the most common underlying conditions, occurring in 26 subjects. Multinomial logistic analysis only identified HAS-BLED score as an independent influencing factor (p = 0.04) for a late discharge. After 60 days, mortality tended to be greatest in the late discharge group (S: 0.0% vs. E: 1.0% vs. R: 1.2% vs. L: 3.3%, p = 0.1066). Over half of the subjects receiving an Amplatzer Amulet occluder were discharged within 1 day of the implant procedure. Serious adverse events were a major trigger for a late discharge after LAAO. Increased HAS-BLED score was associated with a prolonged in-hospital stay.

Déclaration de conflit d'intérêts

The authors have read the journal’s policy and have the following competing interests: JENK has served as a proctor for Abbott and is a consultant for Abbott and Boston Scientific. PM has served as a consultant for Abbott, Boston Scientific, and Medtronic. SB has served as a proctor for Abbott. SF has served as a proctor for Biotronik and Boston Scientific and is a consultant for Abbott and employee of Harzklinikum Dorothea Christiane Erxleben GmbH. JL has served as a proctor for Abbott. MM has served as a proctor for Abbott, Boston Scientific, and Edwards Lifesciences. DHS has served as a proctor and consultant for Abbott. RG and HZ are employees of Abbott. TZ has received consulting fees, travel expenses or study honorariums from Medtronic and Edwards Lifesciences outside of this work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.